<DOC>
	<DOCNO>NCT00003846</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use x-rays damage tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Peripheral stem cell transplantation may allow doctor give high dos radiation therapy chemotherapy kill tumor cell . PURPOSE : Phase II trial study effectiveness radiation therapy , chemotherapy peripheral stem cell transplantation treat patient primitive neuroectodermal tumor .</brief_summary>
	<brief_title>Radiation Therapy , Chemotherapy , Peripheral Stem Cell Transplantation Treating Patients With Primitive Neuroectodermal Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety postradiotherapy high-dose consolidation chemotherapy peripheral blood stem cell ( PBSC ) support patient high-risk primitive neuroectodermal tumor . - Determine safety delay radiotherapy approximately one month patient . - Determine maximum tolerate dose thiotepa patient . - Determine toxic effect intensive chemotherapy PBSC support patient . - Assess time hematopoietic recovery PBSC infusion intensive chemotherapy use craniospinal radiotherapy patient . - Determine overall event-free survival patient treat regimen . OUTLINE : This dose-escalation study thiotepa consolidation therapy . - Induction : Within 31 day initial surgery , patient receive induction therapy comprise vincristine IV day 0 , cyclophosphamide IV 2 hour day 0 1 , filgrastim ( G-CSF ) subcutaneously ( SC ) begin day 2 continue least 7-10 day . Peripheral blood stem cell ( PBSC ) collect . - Chemoradiotherapy : After blood cell count recover , within 28 day start induction , patient begin chemoradiotherapy . Patients receive vincristine IV weekly 8 dos . Radiotherapy administer 5 day week , 6 week , begin within week start vincristine . - Consolidation : Therapy begin 4-6 week last radiation treatment absence disease progression . The first third course comprise vincristine IV day 0 , carboplatin IV 1 hour day 0 1 , thiotepa IV 3 hour day 2-4 , G-CSF SC daily begin day 7 . PBSC reinfused day 7 . The second course comprises vincristine IV day 0 , carboplatin IV 1 hour day 0 1 , cyclophosphamide IV 2 hour day 2 3 , G-CSF SC daily begin day 5 . PBSC reinfused day 5 . Each course last 21 day . For consolidation therapy , cohort 6-12 patient receive escalate dos thiotepa maximum tolerate dose ( MTD ) determine . The MTD define dose 2 12 patient experience dose-limiting toxicity . Patients follow every 3 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 24-56 patient accrue study .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven primitive neuroectodermal tumor ( PNET ) one follow type : Atypical teratoid/rhabdoid tumor Medulloblastoma Desmoplastic medulloblastoma Ependymoblastoma Medullomyoblastoma Spongioblastoma Spongioblastoma polare Primitive polar spongioblastoma Medulloepithelioma Neuroblastoma Pineoblastoma Posterior fossa PNET must M13 M0 great 1.5 cm2 residual disease Non posterior fossa PNET type must M03 If M3 , must show clear evidence tumor MRI No marrow involvement extraneural metastases No M4 disease No cord compression require emergency radiotherapy PATIENT CHARACTERISTICS : Age : 3 21 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,000/mm^3 Platelet count least 150,000/mm^3 ( platelet transfusion ) Hemoglobin least 10 g/dL ( red blood cell transfusion allow ) Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) AST ALT less 2.5 time ULN Renal : Creatinine clearance glomerular filtration rate least 70 mL/min Cardiovascular : Shortening fraction great 27 % echocardiogram OR Ejection fraction great 47 % MUGA Pulmonary : FEV_1/FVC great 60 % except child : Are uncooperative Have dyspnea rest Have exercise intolerance Have pulse oximetry great 94 % room air Other : Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Steroids increase intracranial pressure allow Radiotherapy : See Disease Characteristics No prior urgent radiotherapy Surgery : Not specify Other : No prior therapy tumor</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>regional neuroblastoma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
	<keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>untreated childhood medulloblastoma</keyword>
	<keyword>newly diagnose childhood ependymoma</keyword>
</DOC>